How China Will Score Factory Inspections From 1 November 2026

When an international medical-device distributor, OEM brand owner, or procurement engineer evaluates a Chinese manufacturing partner, supplier audit packs frequently include audit reports, compliance certificates, or gap assessments. On 15 September 2026—just five days before this writing—NMPA published Guo Yao Jian Xie Guan [2026] No. 14 (Medical Device Good Manufacturing Practice Inspection Guiding Principles) ¹. Within two days, consultancy explainers such as Pure Global's 17 September 2026 brief were already treating the 200-item table as the buyer-facing English summary ⁸.

However, accepting an audit scorecard without verifying the governing legal instrument, the audit date, and the product class introduces severe regulatory exposure. A certificate claiming a factory 'passed an NMPA Notice 14 inspection' in September or October 2026 is an impossibility: the regulation does not take legal effect until 1 November 2026. Furthermore, search engine summaries and initial consultancy briefs have already introduced critical misconceptions. Automated AI summaries assert that a factory must achieve zero nonconformities to pass a production-license audit, and conflate an initial license verification failure with the immediate operational shutdown of an active production line. Both assertions misstate the plain text of the regulation.

English search results compound that mix-up. The NMPA English page that ranks for inspection-guide queries is the 7 November 2025 Announcement 107 requirement-file summary ⁶, and a 4 June 2020 English page still describes the standalone-software on-site inspection instrument—not Notice 14 ⁷. Neither URL is Guo Yao Jian Xie Guan [2026] No. 14.

This buyer guide establishes the precise legal status of China's medical-device GMP inspection instruments as of 20 September 2026. We examine the 200 graded items in Notice 14, explain the exact pass/fail thresholds for production licenses versus post-market audits, dissect the dual-release requirements for contract manufacturing, and demonstrate why sterile consumables—such as circumcision staplers or laser fibers—remain subject to a pending sterile annex revision. A structured verification checklist is provided to help international teams review incoming supplier audit packs.

If a factory pack cites the 2026 inspection guiding principles on 20 September 2026, which instrument is actually in force that day?

If a Chinese medical-device supplier presents an audit report or self-assessment dated September 2026 that claims compliance with the 'new 2026 GMP Inspection Guiding Principles', the first technical check is to distinguish between promulgation and statutory implementation. As of 20 September 2026, Notice 14 has been issued (14 September) and published (15 September), but it does not apply until 1 November 2026 ¹.

Between publication on 15 September 2026 and application on 1 November 2026 (42 days remaining from 20 September 2026), the on-site inspection file remains CFDA Shi Yao Jian Xie Jian [2015] No. 218, published on 25 September 2015 ⁴. Official production-license verification and post-market inspections completed before 1 November 2026 are still scored under the current GMP and 2015 No. 218.

Notice 14 provides specific transitional instructions for regulatory authorities during this interim window: provincial inspectors are authorized to 'refer to' (参照) the new guiding principles during current inspections to help enterprises benchmark their readiness for the revised GMP (Announcement No. 107 of 2025) ⁵ and recommend voluntary rectifications. However, formal administrative pass/fail determinations must adhere to the 2015 instrument until 1 November 2026, when Notice 218 will be officially repealed ¹.

What did 15 September 2026 change, and why does Notice 14 still wait until 1 November 2026 to score inspections?

The publication of Notice 14 on 15 September 2026 resolved months of regulatory uncertainty that began with the release of the revised overarching GMP (Announcement No. 107 of 2025) in November 2025 ⁵ and the subsequent public consultation on draft inspection criteria in June 2026 ³. International distributors evaluating factory qualification previously had to rely on our analysis of how to qualify a Chinese medical-device factory after Announcement 107, which noted that the specific scoring rules were still in consultation.

Notice 14 issues a 200-item inspection checklist and the result rules provincial regulators will use once both instruments apply. NMPA aligned that application date with Announcement 107: 1 November 2026. Notice 14 is the scoring file for the 132-article GMP text; it is not a second set of manufacturing obligations. Until 1 November, item 2 of the notice still uses the current GMP for license verification and only authorizes inspectors to refer to (参照) the new guiding principles to assess 107-readiness and recommend rectification—not to issue a statutory Notice 14 pass.

Crucially, Notice 14 specifies how pending administrative applications must transition across the 1 November threshold:

• Applications accepted and inspected before 1 November: Production license applications that undergo on-site inspection prior to 1 November 2026 are evaluated and decided under the current (2015) GMP standards.
• Pending uninspected applications: Applications accepted by MPAs before 1 November 2026 for which on-site inspection has not yet been initiated will be inspected under the revised GMP (Announcement 107 / Notice 14) from 1 November onward.
• Applications with incomplete rectifications: If an on-site inspection was completed prior to 1 November but an administrative decision was deferred pending enterprise rectification, and rectification is not verified before 1 November, the subsequent re-inspection or evaluation switches to the revised GMP framework.
• Class I filing verification clock: For Class I filings, municipal and provincial regulators must conduct an on-site inspection of technical dossiers and GMP implementation within three months of filing. Filings accepted before 1 November that remain uninspected by that date will be inspected under the revised standard.

How do the 200 items split into 39 critical, 88 major and 73 general, and why is a license pass not limited to zero findings?

The core of Notice 14 is its annex document, which establishes exactly 200 inspection items derived from the 15 chapters of Announcement 107 ². Each item is classified into one of three risk tiers, denoted by typographical symbols in the official text:

• Critical items (关键项目, marked ***): 39 items. The annex defines these as items with a material effect on the quality-management system whose nonconformity will lead to product quality and safety risk. Dual-release cells 155, 157, 174 and 175 are among the named critical items in that annex.
• Major items (主要项目, marked **): 88 items. The annex defines these as items with a substantial effect on the quality-management system whose accumulated nonconformities will lead to product quality and safety risk.
• General items (一般项目, marked *): 73 items. The annex defines these as items with some effect on the quality-management system whose nonconformity may lead to product quality and safety risk. They are not merely administrative defects.

A widespread error in early commentary and AI-generated search summaries is the claim that a factory can only pass a production license verification if it achieves zero nonconformities. That assertion contradicts Section III of the official Notice 14 annex ².

Under Notice 14, a production-license verification (including change and renewal) is 通过核查 (pass) if the inspection finds no critical nonconformity, no major nonconformity, and fewer than 5 general nonconformities. Those general findings, if any, are corrected by the enterprise and explained in its annual self-inspection report; they do not by themselves prevent a pass. A specified-deadline rectification plus follow-up inspection is the next conclusion—整改后复查—not the pass rule.

When does a license verification fail, and why is that not the same as post-market production suspension?

Notice 14 establishes a mathematically harmonized threshold for severe noncompliance across both pre-market licensing and post-market surveillance. Under Section III, an inspection results in the most severe administrative classification if any one of the following four objective triggers is met ²:

1. Fraud or Concealment: The enterprise provides false information, falsifies raw production/testing data, or conceals true manufacturing conditions.
2. Critical Deficiencies Threshold: Nonconformities are identified in 3 or more critical items (≥3 ***).
3. Combined High-Risk Deficiencies: Nonconformities across critical and major items total 10 or more (Critical + Major ≥ 10).
4. Total Deficiencies Ceiling: Total nonconformities across all three tiers (critical, major, and general) reach 20 or more (Total ≥ 20).

While these four numerical triggers are identical, their legal consequences diverge fundamentally based on the inspection context:

• In production-license verification (生产许可核查), including change and renewal: any of those four triggers is 未通过核查 (fail). That is an inspection outcome for the application under review. Notice 14 does not equate a fail with automatic revocation of an existing licence. Separate violations are handled under the Regulations on the Supervision and Administration of Medical Devices, the Provisions on Supervision and Administration of Medical Device Manufacturing, and other applicable rules.
• In post-market supervision (上市后监督检查), full-scope or partial-scope: the same four triggers are 暂停生产整改 (suspend production to rectify). The regulator must require the enterprise to pause production; production may resume only after all findings are corrected and a follow-up inspection is passed. The registrant or record-filing holder must also assess product quality and safety risk and recall affected products if necessary. Partial-scope inspections use the same result rules; they are not a more lenient scoring file.

Section IV adds two judgment rules that counts alone do not replace. Interrelated findings that may cause a systemic quality-management risk are treated as a critical finding in the quality-assurance (质量保证) chapter—not as a Chapter 11 quality-control roll-up. A nonconformity repeated from the previous two inspections may be raised by one risk grade, depending on the circumstances ².

Why are sterile, implant, IVD, custom-denture and standalone-software annex inspection guides not in this file?

For buyers of sterile surgical consumables, the load-bearing boundary is item 5 of the notice: from 1 November 2026, sterile, implant, IVD-reagent, custom-denture and standalone-software (独立软件) production must meet both the revised GMP and the corresponding current GMP annexes, and the corresponding inspection guiding principles will be revised and issued separately ¹.

The official Chinese sentence is: 无菌、植入、体外诊断试剂、定制式义齿、独立软件类医疗器械生产质量管理应当同时符合新修订《规范》和相应现行《规范》附录要求。相应检查指导原则另行修订发布。 That list is 独立软件 (standalone software), not a broader “medical device software” family, and the follow-on sentence is 另行修订发布—revised and issued separately—with no date in Notice 14.

This paragraph establishes three vital operational facts:

1. Current annexes remain applicable: From 1 November 2026, sterile-device production quality management must meet both the revised GMP and the corresponding current GMP annex. Notice 14 does not repeal that annex.
2. The 200-item annex is the general scoring file: Independent review of the official annex on 20 September 2026 found 200 serials and the 39/88/73 grade split. The specialised category names in item 5 of the notice (无菌, 植入, 体外诊断试剂, 定制式义齿, 独立软件) do not appear as inspection-item families inside that annex.
3. Specialised inspection guiding principles are still pending: Notice 14 gives no publication date. A sterile-line pack that offers only the general 200-item file is therefore incomplete. A certificate claiming that sterile-barrier and sterilization processes were already 'scored and approved under Notice 14' overstates what this file contains.

Worked SKUs: Circum-CARE Class I three-month filing versus an EO-sterile circumcision stapler or 1470 nm fiber still waiting for a sterile annex GP

The clocks and annex boundary are easier to apply on named Weihai SKUs than on a generic China QMS calendar. The examples below are identity and inspection-file hypotheses, not claimed Notice 14 inspection outcomes.

Case 1: Class I filing (Circum-CARE Post-op Protective Pants). The public product page records NMPA Class I filing Lu Wei Mech Filing 20190014 and does not list a sterile claim ⁹. Notice 14 item 3 requires an on-site inspection of the submitted materials and GMP implementation within three months after a Class I production filing. Filings made before 1 November 2026 that have not yet been inspected switch to the revised GMP from that date. Item 5's specialised list does not name this garment family. This is the three-month filing-inspection worked example, not a claim that the 2019 filing is still inside a live three-month window.

Case 2: Class II EO-sterile surgical consumables (disposable circumcision stapler and circumcision ring). The public stapler page records NMPA Class II Lu Mech Reg. 20192020192 and factory EO sterilization ¹⁰. The circumcision ring (Lu Mech Reg. 20172020238) is likewise Class II and EO-sterilized, with a public CE field. For these lines, Notice 14's 200 items are the general baseline. Item 5 still requires the corresponding current GMP annex, and the corresponding inspection guiding principle has not yet been issued. A pack that offers only the general 200-item checklist is incomplete.

Case 3: Class II sterile vascular consumable (1470 nm medical laser fiber). The public fiber page records NMPA Class II Lu Mech Reg. 20192010517 and a sterile single-use claim; it does not publish an EO cycle identity. Treat it as a sterile-annex-not-this-file hypothesis: the 200-item file is the general baseline, and item 5 keeps the corresponding annex inspection guiding principle on a later revision. The capital console paired with this fiber—NOVACURE (Guo Xie Zhu Zhun 20253011190)—is held by Guangdong Yunshang and is partner-supplied. It is outside Medison's manufacturing scope and is not scored from this article's Weihai factory pack.

Which dual-release cells in the annex (items 157, 174, 175) a contract-manufacturing pack must show without rebuilding Announcement 107?

One of the most significant structural reforms introduced in Announcement 107 was the formalization of China's Dual-Release System (双重放行制度) for medical devices produced under contract manufacturing or Marketing Authorization Holder (MAH) delegation. Under Articles 104 and 113 of Announcement 107, a commercial lot manufactured by a contract facility cannot enter clinical use or commercial distribution based solely on the factory's internal release; it requires a two-step release architecture ⁵.

Notice 14 translates these statutory requirements into concrete, auditable Critical Inspection Items (***) in the official annex ². International buyers engaging Chinese contract manufacturers or sourcing private-label OEM lines must verify that the factory's quality agreement and release procedures reflect four specific items:

1. Item 155 (11.10.1 — Critical ***, Article 104): The enterprise must establish a product-release procedure and, before an authorised person signs the release form, confirm at least: (1) all specified process steps are complete; (2) batch production records are complete; (3) quality-control records are complete, results meet requirements, and the records have been signed as specified; (4) nonconforming product, rework, repair, downgrade and emergency-release special cases have been handled as specified; and (5) the IFU, labels and versions, and unique-device-identifier coding (医疗器械唯一标识赋码) meet requirements (see whether this China Class II shipment needs a UDI yet).
2. Item 157 (11.10.3 — Critical ***, Article 104): For contract manufacturing, product release includes production release and listing release. The registrant or record-filing holder is responsible for listing release; the contract manufacturer is responsible for production release.
3. Item 174 (12.7.1 — Critical ***, Article 113): The delegator must establish a listing-release procedure, review process records, quality-control records and the contractor's production-release file, and sign before listing. The annex prints: 产品上市放行由委托方自行完成，不得委托其他企业进行 (listing release is completed by the delegator and shall not be delegated to other enterprises).
4. Item 175 (12.7.2 — Critical ***, Article 113 as printed): The contractor must establish a production-release procedure, review process and quality-control records, and obtain an authorised signature before the batch leaves the factory.

Distributor checklist: accept, ask-for-date-and-annex, or send-back-if-June-draft-or-pre-November-certificate

When an international distributor or OEM buyer receives a factory qualification dossier from a Chinese manufacturer, the review team must execute a systematic three-stage triage: Accept, Ask for Date and Annex, or Send Back. Do not allow marketing claims of 'full 2026 GMP certification' to bypass documentary due diligence.

Where VEMERIX fits—and where due diligence still begins

VEMERIX is the international brand of Weihai Medison Medical Equipment Co., Ltd., positioned as a Minimally Invasive Surgery Total Solution Platform serving urology, vascular surgery and perioperative care. Public product pages record NMPA-registered disposable circumcision devices and staplers (Lu Mech Reg. 20192020192 / 20172020238) ¹⁰, Class I Circum-CARE garments (Lu Wei Mech Filing 20190014) ⁹, and 1470 nm medical laser fibers (Lu Mech Reg. 20192010517), paired with a partner-supplied laser console. Those pages do not publish a Notice 14 inspection outcome.

This article does not claim that VEMERIX has undergone or passed an NMPA Notice 14 statutory inspection. On 20 September 2026, Notice 14 is issued and published but does not yet apply, so a statutory Notice 14 pass is not an available inspection outcome. Inspectors may already refer to Notice 14 only to assess Announcement 107 readiness. Due diligence still begins with the labelled inspection date, the operating model, and whether a specialised annex applies.

Request the named inspection instrument and date, the factory operating model, and—where the SKU is sterile—the current annex file, through Quality, Downloads, or Contact. A Notice 14 readiness discussion is not a substitute for that labelled pack.

Frequently asked questions

Is China's new GMP inspection guide already the scoring law on 20 September 2026?

No. While NMPA Guo Yao Jian Xie Guan [2026] No. 14 was published on 15 September 2026, its formal implementation date is 1 November 2026. Until that date, CFDA Shi Yao Jian Xie Jian [2015] No. 218 remains the legally binding on-site inspection file for all official production licensing and routine surveillance inspections. Notice 14 may only be referenced informally by inspectors to evaluate enterprise readiness for Announcement 107.

Does a license inspection fail automatically cancel an existing production licence?

No. 未通过核查 applies to the production-license application under review (including change and renewal). Notice 14 does not equate that fail with automatic revocation of an existing licence. Separate violations are handled under the medical-device supervision regulations and manufacturing-supervision provisions, not by collapsing fail into revocation.

Can a factory pass a Notice 14 license verification with some general findings?

Yes. 通过核查 is no critical finding, no major finding, and fewer than 5 general findings. Any such general findings are corrected by the enterprise and explained in the annual self-inspection report. Search summaries that treat pass as zero findings only are incorrect.

Does the 200-item file cover a sterile circumcision stapler or 1470 nm fiber without a separate annex GP?

No. Item 5 keeps sterile, implant, IVD-reagent, custom-denture and standalone-software annex inspection guiding principles on a later revision. The 200 items are the general scoring file. A sterile circumcision stapler or 1470 nm fiber pack still needs the corresponding current GMP annex evidence; the 200-item checklist alone is not that file.

Does a Class I Circum-CARE filing wait until 1 November 2026 for any inspection?

No. Item 3 requires an on-site inspection within three months after a Class I production filing. Uninspected pre-1 November filings switch to the revised GMP from that date. Circum-CARE is the named Class I example because the public page records Lu Wei Mech Filing 20190014, not because this article claims a live three-month inspection is due on 20 September 2026.

Is the 9 June 2026 consultation still the document to request?

No. The 9 June 2026 document was a draft for public comment with feedback closing on 24 June 2026. It has been completely superseded by the final, official release of Guo Yao Jian Xie Guan [2026] No. 14 on 15 September 2026. Any supplier dossier referencing the June consultation is obsolete and should be rejected.

Does VEMERIX claim a Notice 14 inspection pass in this article?

No. Public VEMERIX product pages record NMPA registrations and filings; they do not publish a Notice 14 inspection pass. Notice 14 does not apply until 1 November 2026. A supplier certificate dated before that day and offered as a statutory Notice 14 pass should be sent back.

Is an ISO 13485 or MDSAP certificate the Notice 14 scoring file?

No. ISO 13485 and MDSAP are third-party QMS audit programmes. They are not Guo Yao Jian Xie Guan [2026] No. 14, and they do not replace a provincial GMP on-site inspection under the Chinese scoring file that actually applies on the labelled inspection date. See how to verify an ISO 13485 certificate.